Berberine Synergizes with Cisplatin via Inducing Apoptosis on A549 non-Small Cell Lung Cancer Cells


Abstract views: 368 / PDF downloads: 205

Authors

DOI:

https://doi.org/10.58600/eurjther1703

Keywords:

Berberine (BBR), Cisplatin (CIS), synergism, A549, apoptosis

Abstract

Objective: Lung cancer is the most common cause of morbidity and mortality. Platinum-based chemotherapy, which is the primary line of treatment, offers limited benefit due to drug resistance and side effects. Berberine (BBR), which is characterised by its potent and safe anticancer activity, represents a promising combination option in chemotherapy. To overcome the limitations in lung cancer chemotherapy, we investigated whether BBR and cisplatin (CIS) exert synergistic effects on non-small cell lung cancer cell line (A549) based on cytotoxicity and apoptotic response markers.

Methods: The potential cytotoxic effects of the combination treatment were evaluated using the MTT and Chou-Talalay methods. Elisa assays were also performed to measure the levels of the pro-apoptotic protein Bax and the effector protein caspase (Cas)-3.

Results: The results showed that BBR alone reduced A549 cell viability in a dose-dependent manner and synergized with CIS (CI =0.34±0.05 at IC50 concentrations). Elisa results showed that the combined treatment (both at IC50 concentrations) modulated apoptotic signalling pathways in A549 cells. Bax and Cas3 protein levels were dramatically enhanced in A549 cells treated with CIS +BBR compared to control (0.5% DMSO) (p < 0.001).

Conclusion: Our results suggest that BBR can synergistically enhance the therapeutic effect of CIS in A549 cells. The potential therapeutic efficacy of BBR as part of a combination in current chemotherapy should be supported by in-depth research and clinical studies on the molecular mechanisms associated with cancer.

Metrics

Metrics Loading ...

References

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: An overview. Int J Cancer. 149:778-789. https://doi.org/10.1002/ijc.33588

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209-249. https://doi.org/10.3322/caac.21660

Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 5(3):288-300. https://doi.org/10.21037/tlcr.2016.06.07

Barta JA, Powell CA, Wisnivesky JP (2019) Global Epidemiology of Lung Cancer. Ann Glob Health. 85(1):8. https://doi.org/10.5334/aogh.2419

Jones GS, Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med (Lond).18(Suppl 2):41-46. https://doi.org/10.7861/clinmedicine.18-2-s41

Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R (2015) Non-small-cell lung cancer. Nat Rev Dis Primers. 1:15009. https://doi.org/10.1038/nrdp.2015.9

Achi IT, Sarbadhikary P, George BP, Abrahamse H (2022) Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment. Cells. 11(21):3433. https://doi.org/10.3390/cells11213433

Becit M, Aydin S (2020) An In Vitro Study on the Interactions of Pycnogenol® with Human Cervical Cancer Cells. Turk J Pharm Sci. 17(1):1-6. https://doi.org/10.4274/tjps.galenos.2018.97759

Negrette-Guzmán M (2019) Combinations of the antioxidants sulforaphane or curcumin and the conventional antineoplastics cisplatin or doxorubicin as prospects for anticancer chemotherapy. Eur J Pharmacol. 859:172513. https://doi.org/10.1016/j.ejphar.2019.172513

Patra S, Pradhan B, Nayak R, Behera C, Das S, Patra SK, Efferth T, Jena M, Bhutia SK (2021) Dietary polyphenols in chemoprevention and synergistic effect in cancer: Clinical evidences and molecular mechanisms of action. Phytomedicine. 90:153554. https://doi.org/10.1016/j.phymed.2021.153554

Chen Z, Vallega KA, Chen H, Zhou J, Ramalingam SS, Sun SY (2022) The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. Pharmacol Res. 175:105998. https://doi.org/10.1016/j.phrs.2021.105998

Xu F, Liu M, Liao Y, Zhou Y, Zhang P, Zeng Y, Liu Z (2022) Improvement of anticancer effect of berberine by salt formation modifications. Phytomedicine. 104:154314. https://doi.org/10.1016/j.phymed.2022.154314

Guamán Ortiz LM, Tillhon M, Parks M, Dutto I, Prosperi E, Savio M, Arcamone AG, Buzzetti F, Lombardi P, Scovassi AI (2014) Multiple effects of berberine derivatives on colon cancer cells. Biomed Res Int. 2014:924585. https://doi.org/10.1155/2014/924585

Imenshahidi M, Hosseinzadeh H (2019) Berberine and barberry (Berberis vulgaris): A clinical review. Phytother Res. 33(3):504-523. https://doi.org/10.1002/ptr.6252

Song D, Hao J, Fan D (2020) Biological properties and clinical applications of berberine. Front Med. 14(5):564-582. https://doi.org/10.1007/s11684-019-0724-6

Zhu Y, Xie N, Chai Y, Nie Y, Liu K, Liu Y, Yang Y, Su J, Zhang C (2022) Apoptosis Induction, a Sharp Edge of Berberine to Exert Anti-Cancer Effects, Focus on Breast, Lung, and Liver Cancer. Front Pharmacol. 13:803717. https://doi.org/10.3389/fphar.2022.803717

Zhang C, Sheng J, Li G, Zhao L, Wang Y, Yang W, Yao X, Sun L, Zhang Z, Cui R (2020) Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review. Front Pharmacol. 10:1461. https://doi.org/10.3389/fphar.2019.01461

Liu Y, Liu X, Zhang N, Yin M, Dong J, Zeng Q, Mao G, Song D, Liu L, Deng H (2020) Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B. 10(12):2299-2312. https://doi.org/10.1016/j.apsb.2020.06.014

Devarajan N, Jayaraman S, Mahendra J, Venkatratnam P, Rajagopal P, Palaniappan H, Ganesan SK (2021) Berberine-A potent chemosensitizer and chemoprotector to conventional cancer therapies. Phytother Res. 35(6):3059-3077. https://doi.org/10.1002/ptr.7032

Cuan X, Yang X, Zhu W, Zhao Y, Luo R, Huang Y, Wang X, Sheng J (2023) Antitumor effects of erlotinib in combination with berberine in A431 cells. BMC Pharmacol Toxicol. 24(1):29. https://doi.org/10.1186/s40360-023-00661-2

Liu L, Fan J, Ai G, Liu J, Luo N, Li C, Cheng Z (2019) Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 52(1):37. https://doi.org/10.1186/s40659-019-0243-6

Zheng X, Zhao Y, Jia Y, Shao D, Zhang F, Sun M, Dawulieti J, Hu H, Cui L, Pan Y, Yang C, Sun W, Zhang S, He K, Li J, Du J, Zhang M, Chen L (2021) Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis. Biomaterials. 271:120716. https://doi.org/10.1016/j.biomaterials.2021.120716

Jiang G, Li L, Wu X, Dong S, Tong X (2015) [Influence of Berberine on Cisplatin Antineoplastic Effect in A549 Cells]. Zhongguo Fei Ai Za Zhi. 18(8):481-6. Chinese. https://doi.org/10.3779/j.issn.1009-3419.2015.08.03

Zhu T, Li LL, Xiao GF, Luo QZ, Liu QZ, Yao KT, Xiao GH (2015) Berberine Increases Doxorubicin Sensitivity by Suppressing STAT3 in Lung Cancer. Am J Chin Med. 43(7):1487-502. https://doi.org/10.1142/S0192415X15500846

Mao J, Cheng W, Yang Y, Jin Q, Wang J 2020 Cisplatin in combination with berberine suppresses lung cancer cell A549 growth through induction of DNA damage and ROS-dependent apoptosis. Chinese Pharmacological Bulletin. 36(6):844-851. https://doi.org/10.3969/j.issn.1001-1978.2020.06.020

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65(1-2):55-63. https://doi.org/10.1016/0022-1759(83)90303-4

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27-55. https://doi.org/10.1016/0065-2571(84)90007-4

Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A (2023) Lung Cancer Treatment Advances in 2022. Cancer Invest. 41(1):12-24. https://doi.org/10.1080/07357907.2022.2119479

Kumar R, Awasthi M, Sharma A, Padwad Y, Sharma R (2020) Berberine induces dose-dependent quiescence and apoptosis in A549 cancer cells by modulating cell cyclins and inflammation independent of mTOR pathway. Life Sci. 244:117346. https://doi.org/10.1016/j.lfs.2020.117346

Chen Q, Hou Y, Li D, Ding Z, Xu X, Hao B, Xia Q, Li M, Fan L (2022) Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway. Ann Transl Med. 10(8):485. https://doi.org/10.21037/atm-22-1298

Lu JJ, Fu L, Tang Z, Zhang C, Qin L, Wang J, Yu Z, Shi D, Xiao X, Xie F, Huang W, Deng W (2016) Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells. Oncotarget. 7(3):2985-3001. https://doi.org/10.18632/oncotarget.6407

Meng M, Geng S, Du Z, Yao J, Zheng Y, Li Z, Zhang Z, Li J, Duan Y, Du G (2017) Berberine and cinnamaldehyde together prevent lung carcinogenesis. Oncotarget. 8(44):76385-76397. https://doi.org/10.18632/oncotarget.20059

Chen P, Dai CH, Shi ZH, Wang Y, Wu JN, Chen K, Su JY, Li J (2021) Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis. Apoptosis. 26(11-12):639-656. https://doi.org/10.1007/s10495-021-01694-w

Peng PL, Kuo WH, Tseng HC, Chou FP (2008) Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys. 70(2):529-42. https://doi.org/10.1016/j.ijrobp.2007.08.034

Liu Y, Yu H, Zhang C, Cheng Y, Hu L, Meng X, Zhao Y (2008) Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur J Cancer. 44(16):2425-32. https://doi.org/10.1016/j.ejca.2008.07.040

Li J, Liu F, Jiang S, Liu J, Chen X, Zhang S, Zhao H (2018) Berberine hydrochloride inhibits cell proliferation and promotes apoptosis of non-small cell lung cancer via the suppression of the MMP2 and Bcl-2/Bax signaling pathways. Oncol Lett. 15(5):7409-7414. https://doi.org/10.3892/ol.2018.8249

Ni L, Sun P, Fan X, Li Z, Ren H, Li J (2022) Berberine Inhibits FOXM1 Dependent Transcriptional Regulation of POLE2 and Interferes With the Survival of Lung Adenocarcinoma. Front Pharmacol. 12:775514. https://doi.org/10.3389/fphar.2021.775514

Burke PJ (2017) Mitochondria, Bioenergetics and Apoptosis in Cancer. Trends Cancer. 3(12):857-70. https://doi.org/10.1016/j.trecan.2017.10.006

Ni L, Li Z, Ren H, Kong L, Chen X, Xiong M, Zhang X, Ning B, Li J (2022) Berberine inhibits non-small cell lung cancer cell growth through repressing DNA repair and replication rather than through apoptosis. Clin Exp Pharmacol Physiol. 49(1):134-144. https://doi.org/10.1111/1440-1681.13582

Sung JH, Kim JB, Park SH, Park SY, Lee JK, Lee HS, Chung N (2012) Berberine decreases cell growth but increases the side population fraction of H460 lung cancer cells. J. Korean Soc. Appl. Biol. Chem. 55, 491–495. https://doi.org/10.1007/s13765-012-2119-0

Majidzadeh H, Araj-Khodaei M, Ghaffari M, Torbati M, Ezzati Nazhad Dolatabadi J, Hamblin MR (2020) Nano-based delivery systems for berberine: A modern anti-cancer herbal medicine. Colloids Surf B Biointerfaces. 194:111188. https://doi.org/10.1016/j.colsurfb.2020.111188

Downloads

Published

2023-07-27

How to Cite

Becit Kızılkaya, M., Öncü, Şeyma, Şen, S., & Çelik, S. (2023). Berberine Synergizes with Cisplatin via Inducing Apoptosis on A549 non-Small Cell Lung Cancer Cells . European Journal of Therapeutics, 29(3), 480–488. https://doi.org/10.58600/eurjther1703

Issue

Section

Original Articles

Categories